Search Result

Results for "

Mitochondrial bioenergetics

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Mitochondrial Metabolism (9) Apoptosis (5) Aurora Kinase (2) Autophagy (8) Bcl-2 Family (1) Carnitine Palmitoyltransferase (CPT) (1) CFTR (5) HSP (2) Isotope-Labeled Compounds (2) Microtubule/Tubulin (2) NO Synthase (1) Oxidative Phosphorylation (2) P-glycoprotein (5) PDHK (1) Polo-like Kinase (PLK) (2) Potassium Channel (5) Reactive Oxygen Species (ROS) (2) Reference Standards (1) ROCK (1)
By Research Areas:	Cancer (6) Metabolic Disease (5) Neurological Disease (3)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Mitochondrial Metabolism Mitophagy

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-15206

Glibenclamide Maximum Cited Publications 27 Publications Verification Glyburide	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-134832

Mito-LND 3 Publications Verification Mito-Lonidamine	Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species (ROS) Autophagy	Cancer
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells .

HY-N3383

Ligustroside Ligstroside	Mitochondrial Metabolism	Neurological Disease
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

HY-10996A

KHS101 hydrochloride 1 Publications Verification	Autophagy HSP Apoptosis Aurora Kinase Microtubule/Tubulin Polo-like Kinase (PLK)	Neurological Disease Cancer
KHS101 is a blood-brain barrier-penetrant anticancer agent that primarily functions by inhibiting HSPD1 (IC₅₀ = 14.4 μM) and TACC3 across different cellular backgrounds. KHS101 promotes the aggregation of HSPD1 with client proteins, destabilizes TACC3, and reduces the levels of TACC3, Aurora A and PLK1. KHS101 induces autophagy, apoptosis, cell cycle exit and neuronal differentiation; it suppresses cancer cell growth, motility, EMT and stemness; it also impairs mitochondrial bioenergetics and glycolysis in glioblastoma cells. KHS101 can be used in research related to glioblastoma multiforme and breast cancer .

HY-15206S1

Glyburide-d3 Glyburide-d₃	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S

Glyburide-d11	Isotope-Labeled Compounds Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-110339

RKI-1447 dihydrochloride 4 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective ROCK inhibitor with IC₅₀s of 14.5 and 6.2 nM for ROCK1 and ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis .

HY-175673

LCB-2151	Carnitine Palmitoyltransferase (CPT) Apoptosis Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Cancer
LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research .

HY-15206R

Glibenclamide (Standard) Glyburide (Standard)	Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Potassium Channel Reference Standards	Metabolic Disease
Glibenclamide (Standard) is the analytical standard of Glibenclamide. This product is intended for research and analytical applications. Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-P10614

Bid BH3 peptide	Apoptosis Bcl-2 Family	Others
Bid BH3 peptide is a small peptide derived from Bid protein that can bind and activate the pro-apoptotic proteins Bax and Bak, leading to mitochondrial outer membrane permeabilization (MOMP) and apoptosis. Bid BH3 peptide can be used to study mitochondrial bioenergetics .

HY-10996

KHS101	HSP Microtubule/Tubulin Aurora Kinase Polo-like Kinase (PLK) Autophagy Apoptosis	Neurological Disease Cancer
KHS101 is a blood-brain barrier-penetrant anticancer agent that primarily functions by inhibiting HSPD1 (IC₅₀ = 14.4 μM) and TACC3 across different cellular backgrounds. KHS101 promotes the aggregation of HSPD1 with client proteins, destabilizes TACC3, and reduces the levels of TACC3, Aurora A and PLK1. KHS101 induces autophagy, apoptosis, cell cycle exit and neuronal differentiation; it suppresses cancer cell growth, motility, EMT and stemness; it also impairs mitochondrial bioenergetics and glycolysis in glioblastoma cells. KHS101 can be used in research related to glioblastoma multiforme and breast cancer .

HY-156109

PDK-IN-2	PDHK Mitochondrial Metabolism	Cancer
PDK-IN-2 (Compound 1F) is a PDK inhibitor (IC₅₀: 68 nM). PDK-IN-2 inhibits the cellular expression of PDK1 and PDK4. PDK-IN-2 enhances mitochondrial bioenergetics, attenuates glycolytic phenotypes, and induces cell apoptosis in the mitochondrial pathway. PDK-IN-2 inhibits tumor growth in 4T1 syngeneic mice model .

HY-P5315

eNOS pT495 decoy peptide	NO Synthase	Others
eNOS pT495 decoy peptide is a specific decoy peptide to prevent T495 phosphorylation reduced eNOS uncoupling and mitochondrial redistribution. eNOS pT495 decoy peptide is used in ventilator-induced lung injury research .

HY-15206S2

Glibenclamide-13C6 Glyburide-¹³C₆	Isotope-Labeled Compounds Autophagy Mitochondrial Metabolism Potassium Channel CFTR P-glycoprotein	Metabolic Disease
Glibenclamide- ¹³C₆ (Glyburide- ¹³C₆) is ¹³C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

Cat. No.	Nombre del producto	Target	Research Area

HY-P10614

Bid BH3 peptide	Apoptosis Bcl-2 Family	Others
Bid BH3 peptide is a small peptide derived from Bid protein that can bind and activate the pro-apoptotic proteins Bax and Bak, leading to mitochondrial outer membrane permeabilization (MOMP) and apoptosis. Bid BH3 peptide can be used to study mitochondrial bioenergetics .

HY-P5315

eNOS pT495 decoy peptide	NO Synthase	Others
eNOS pT495 decoy peptide is a specific decoy peptide to prevent T495 phosphorylation reduced eNOS uncoupling and mitochondrial redistribution. eNOS pT495 decoy peptide is used in ventilator-induced lung injury research .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-N3383

Ligustroside Ligstroside	Monophenols Iridoids Ligustrum japonicum Thunb. Oleaceae Terpenoids Phenols Plants Source Classification	Mitochondrial Metabolism
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

Cat. No.	Nombre del producto	Chemical Structure

HY-15206S1

Glyburide-d3
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S

Glyburide-d11
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-15206S2

Glibenclamide-13C6
Glibenclamide- ¹³C₆ (Glyburide- ¹³C₆) is ¹³C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

Glibenclamide-13C6

Glibenclamide- ¹³C₆ (Glyburide- ¹³C₆) is ¹³C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

Cat. No.	Nombre del producto		Classification

HY-160203

18:0 Cardiolipin		Phospholipids
18:0 Cardiolipin (CL) is a polyglycerophospholipid synthesized in mitochondria, playing a crucial role in mitochondrial bioenergetics and signaling. Exclusively found in the inner mitochondrial membrane of eukaryotes, 18:0 CL exhibits a complex structure characterized by its unique chain length and degree of saturation, along with the specific arrangements of its four fatty acid substituents.

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones